Global Collaboration for Improved Patient Outcomes
Breast Cancer Canada is proud to be at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, where the latest global advances in cancer treatment and research are being unveiled.
Our presence at this prestigious conference allows us to engage with the world’s leading oncologists, researchers, and healthcare professionals to bring back critical insights for the Canadian breast cancer community.
ESMO 2024 serves as a hub for groundbreaking research and collaboration. This year’s conference highlights numerous advances in breast cancer treatment, including innovative therapies and more effective treatment protocols. By participating in these discussions and presentations, Breast Cancer Canada ensures that the voices of Canadian patients and advocates are included in this global conversation.
ENHERTU: A Proven Option for Metastatic Breast Cancer
Among the key topics at ESMO 2024 is ENHERTU, a drug that has proven to be a significant option for patients with metastatic breast cancer, particularly those with brain metastases. This antibody-drug conjugate has been making headlines for offering a new treatment avenue for patients with limited options. Early results indicate improved outcomes for patients, paving the way for more targeted therapies in the future.
In the DESTINY-Breast12 study, Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated that 61% of patients with breast cancer that had spread to the brain experienced no further cancer progression after one year.
Our team is monitoring these developments closely to assess their potential impact on treatment protocols and patient care in Canada.
Reduced Radiation for Early-Stage Breast Cancer
Another exciting advancement highlighted at ESMO 2024 is the move toward reduced radiation therapy for early-stage breast cancer patients. Studies presented at the conference indicate that a more efficient and less intensive radiation treatment can be as effective as the traditional, longer course of therapy. This advancement not only lessens the burden on patients but also minimizes side effects, leading to an improved quality of life.
We are eager to explore how these findings can be translated into practice to benefit patients across Canada.
Stay Tuned for More
Our team is on the ground at ESMO 2024, gathering insights and engaging with experts to ensure we bring the most relevant and impactful information back to the Canadian breast cancer community. Stay tuned for more updates from the conference, where we will continue to report on the latest advancements in breast cancer research and treatment.